New drug combo aims to stop breast cancer return

NCT ID NCT03945721

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adults with residual disease after chemotherapy and surgery. The main goal is to find the safest dose of niraparib when given with radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Niraparib (a PARP inhibitor drug)
What this could lead to: If successful, this could lead to a new treatment option that reduces the risk of breast cancer returning after surgery and radiation.
What could go wrong: This is a very early (Phase 1) trial with only 21 participants, so safety and the right dose are the main focus. It is not yet known if the combination works better than standard care, and side effects from adding niraparib to radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESIDUAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Neoplasm, Residual triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESIDUAL DISEASE TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute/Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.